(Source: Sanofi SA) Paris, France and Tarrytown, New York - July 5, 2016-Sanofi and Regeneron Pharmaceuticals, Inc. announced today that the Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Praluent (alirocumab) for the treatment of uncontrolled low-density lipoprotein (LDL) cholesterol, in certain adult patients with hypercholesterolemia at high cardiovascular risk. Praluent is a human monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). In Japan Praluent is indicated for the treatment of patients with hypercholesterolemia and familial hypercholesterolemia (FH) who are at high cardiovascular risk and in...
↧